

Allergan plc  
Form 8-K  
March 16, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of The Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): March 15, 2016**

**ALLERGAN PLC**

**(Exact name of registrant as specified in its charter)**

**Ireland**  
**(State or other jurisdiction**  
  
**of incorporation)**

**001-36867**  
**(Commission**  
  
**File Number)**

**98-1114402**  
**(IRS. Employer**  
  
**Identification No.)**

**Clonshaugh Business and Technology Park  
Coolock, Dublin, D17 E400, Ireland  
(Address of principal executive offices)**

**N/A  
(Zip Code)**

**(862) 261-7000**

**(Registrant's telephone number, including area code)**

**N/A**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ..  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ..  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ..  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ..  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure.**

On March 15, 2016, Allergan plc ( Allergan ) sent an email to its employees regarding the public announcement by Teva Pharmaceuticals Industries Ltd. ( Teva ) of updated guidance related to the closing of Allergan s divestiture of certain assets to Teva. The text of the email and a copy of the attachment thereto is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed filed for purposes of Section 18 of the Exchange Act of 1934, as amended (the Exchange Act ), or as otherwise subject to liability of that section, nor shall such information be deemed to be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

Exhibit	Description of Exhibit
Exhibit 99.1	Email and attachment sent by Allergan plc to its employees on March 15, 2016.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 15, 2016

**ALLERGAN PLC**

By: /s/ A. Robert D. Bailey

Name: A. Robert D. Bailey

Title: EVP, Chief Legal Officer and Corporate Secretary

**Exhibit Index**

Exhibit	Description of Exhibit
Exhibit 99.1*	Email and attachment sent by Allergan plc to its employees on March 15, 2016.

\* Exhibits filed herewith